Telix Pharmaceuticals has announced the dosing of the first patient in a Phase II study of TLX250-CDx, an imaging agent that targets carbonic anhydrase (CAIX) and is being investigated across a range of cancer indications. The STARBURST study will explore CAIX expression in patients with diverse solid tumours for potential diagnostic and therapeutic applications. Tumours expressing CAIX are typi..
Kymera Therapeutics, a clinical-stage biopharmaceutical company, has released updated clinical data from the phase 1 trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413. The new data shows that both programs continue to demonstrate substantial target knockdown in ongoing clinical trials with no dose limiting toxicities observed. Kymera is developing these drugs to target protein degrada..
Elevation Oncology, a company focused on developing selective cancer therapies for solid tumors with significant unmet medical needs, has announced the pricing of an underwritten public offering of common stock and pre-funded warrants to purchase shares of common stock. The combined offering price is $2.2500 per share of common stock and accompanying warrant and $2.2499 per pre-funded warrant an..
Enochian Biosciences' Cancer Platform on Track for Human Trials by 2024 Enochian Biosciences has announced that its innovative Cancer Platform is expected to undergo clinical trials in humans during the first half of 2024. The US Food and Drug Administration (FDA) recently confirmed this after reviewing Enochian's Pre-Investigational New Drug Application submission. The company’s technology uses..
BioInvent announces additional efficacy data from Phase 1/2 trial with BI-1206 in solid tumors, including one patient with long-lasting stable disease and another experiencing a partial response. The study is testing the novel anti-FcyRIIB antibody in combination with pembrolizumab for patients who have previously progressed on PD-1/PD-L1 immune checkpoint inhibitors. The results suggest that BI..
